S&P 500   3,003.80 (-0.10%)
DOW   26,865.18 (+0.14%)
QQQ   192.41 (-0.51%)
AAPL   240.85 (+0.14%)
MSFT   136.93 (-1.08%)
GOOGL   1,241.08 (-0.26%)
AMZN   1,766.27 (-1.09%)
CGC   21.01 (+3.24%)
NVDA   196.61 (+0.30%)
BABA   169.58 (-2.27%)
TSLA   256.55 (+1.20%)
AMD   31.56 (-1.47%)
T   38.28 (+0.13%)
F   9.06 (+0.33%)
ACB   3.59 (-2.71%)
PRI   126.15 (+0.37%)
NFLX   267.61 (-3.75%)
GILD   66.03 (+1.26%)
DIS   132.97 (+2.08%)
S&P 500   3,003.80 (-0.10%)
DOW   26,865.18 (+0.14%)
QQQ   192.41 (-0.51%)
AAPL   240.85 (+0.14%)
MSFT   136.93 (-1.08%)
GOOGL   1,241.08 (-0.26%)
AMZN   1,766.27 (-1.09%)
CGC   21.01 (+3.24%)
NVDA   196.61 (+0.30%)
BABA   169.58 (-2.27%)
TSLA   256.55 (+1.20%)
AMD   31.56 (-1.47%)
T   38.28 (+0.13%)
F   9.06 (+0.33%)
ACB   3.59 (-2.71%)
PRI   126.15 (+0.37%)
NFLX   267.61 (-3.75%)
GILD   66.03 (+1.26%)
DIS   132.97 (+2.08%)
Log in

GRIFOLS S A/S Stock Price, News & Analysis (NASDAQ:GRFS)

$20.72
-0.06 (-0.29 %)
(As of 10/22/2019 03:32 PM ET)
Today's Range
$20.66
Now: $20.72
$20.80
50-Day Range
$19.54
MA: $20.43
$21.30
52-Week Range
$17.42
Now: $20.72
$23.03
Volume91,781 shs
Average Volume969,017 shs
Market Capitalization$14.25 billion
P/E Ratio17.71
Dividend Yield1.26%
Beta1.06
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRFS
CUSIPN/A
Phone212-969-3335

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.30 billion
Cash Flow$1.56 per share
Book Value$8.07 per share

Profitability

Net Income$704.63 million

Miscellaneous

Employees21,230
Market Cap$14.25 billion
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.


GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S announced a Semi-Annual dividend on Wednesday, May 29th. Investors of record on Monday, June 10th will be given a dividend of $0.14 per share on Tuesday, June 18th. The ex-dividend date is Friday, June 7th. View GRIFOLS S A/S's Dividend History.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

GRIFOLS S A/S shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were distributed to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

How were GRIFOLS S A/S's earnings last quarter?

GRIFOLS S A/S (NASDAQ:GRFS) released its earnings results on Wednesday, July, 31st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.33. The biotechnology company had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.38 billion. GRIFOLS S A/S had a net margin of 11.82% and a return on equity of 14.88%. View GRIFOLS S A/S's Earnings History.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for GRIFOLS S A/S.

What price target have analysts set for GRFS?

4 analysts have issued 1 year price objectives for GRIFOLS S A/S's shares. Their predictions range from $19.00 to $22.50. On average, they expect GRIFOLS S A/S's stock price to reach $20.75 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for GRIFOLS S A/S.

What is the consensus analysts' recommendation for GRIFOLS S A/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S.

Has GRIFOLS S A/S been receiving favorable news coverage?

Media headlines about GRFS stock have trended extremely negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GRIFOLS S A/S earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for GRIFOLS S A/S.

Are investors shorting GRIFOLS S A/S?

GRIFOLS S A/S saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 2,690,000 shares, a decline of 25.9% from the August 30th total of 3,630,000 shares. Based on an average daily volume of 1,250,000 shares, the short-interest ratio is currently 2.2 days. Approximately 1.1% of the company's stock are short sold. View GRIFOLS S A/S's Current Options Chain.

Who are some of GRIFOLS S A/S's key competitors?

What other stocks do shareholders of GRIFOLS S A/S own?

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the folowing people:
  • Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)
  • Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
  • Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)
  • Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.16%), CIBC Private Wealth Group LLC (0.09%), Crossmark Global Holdings Inc. (0.06%), Cardinal Capital Management (0.01%), Regentatlantic Capital LLC (0.00%) and Cibc Bank USA (0.00%).

Which major investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Regentatlantic Capital LLC and Financial Gravity Wealth Inc..

Which major investors are buying GRIFOLS S A/S stock?

GRFS stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Cibc Bank USA, Envestnet Asset Management Inc. and Cardinal Capital Management.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $20.72.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $14.25 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is http://www.grifols.com/.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected]


MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  373 (Vote Underperform)
Total Votes:  641
MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel